Study Evaluating HKI-272 (Neratinib) In Subjects With Advanced Breast Cancer

Institut Jules Bordet Unite du Chimiotherapie, Brussels

St-Augustinus Ziekenhuis Oncology Department, Wilrijk

University Hospital Gasthuisberg, Leuven

Oncology Care Associates, Bethesda

The Cancer Center at GBMC, Baltimore

The Cleveland Clinic Taussig Cancer Center, Cleveland

Nizam's Institute of Medical Sciences, Hyderabad

Midwestern Regional Medical Center, Zion

Louisiana State University, Shreveport

University of Colorado Hospital, Aurora

Institut Gustave ROUSSY Service de Pathologie Mammaire, Villejuif

Virginia Mason Medical Center, Seattle

Cancer Hospital Peking Union Medical College, Beijing

The Hospital Affiliated Academy Military Medical Science, Chinese People's Liberation Army, Beijing

Chinese People's Liberation Army General Hospital, Beijing

N.N. Blokhin Russian Cancer Research Center of RAMS, Moscow

City Oncology Dispensary, Saint Petersburg

City Hospital N 31 Oncology Haematology Dept. For Adults, Saint Petersburg

Breast Tumor Department, N.N. Petrov Research Institute of Oncology, Saint Petersburg

No. 81 Hospital of Chinese People's Liberation Army, Nanjing

Medical Radiological Research Center of RAMS, Department of Radiation and Surgical Methods, Obninsk

Tata Memorial Centre, Mumbai

Jehangir Clinical Development Centre, Pune

Deenanath Mangeshkar Hospital, Pune

Beth Israel Deaconess Medical Center, Boston

Dana Farber Cancer Institute, Boston

Boston University Medical Center, Boston

Faulkner Hospital, Boston

Norris Cotton Cancer Center Dartmouth Hitchcock Medical Center, Lebanon

The Cancer Institute of New Jersey, New Brunswick

Hospital Regional Lic. Adolfo Lopez Mateos Oncología Médica, Mexico City

Arke Estudios Clínicos S.A. de C.V., Mexico City

Hospital de Especialidades MIG, Mexico City